Defining the biological responses of IL-6 by the study of a novel IL-6 receptor chain immunodeficiency

被引：25
|
作者：
Nahum, Amit [1 ,2 ,3 ]
Sharfe, Nigel [7 ,8 ,9 ,10 ]
Broides, Arnon [2 ]
Dadi, Harjit [7 ,8 ,9 ,10 ]
Naghdi, Zahra [7 ,8 ,9 ,10 ]
Mandola, Amarilla B. [1 ,7 ,8 ,9 ,10 ]
Vong, Linda [7 ,8 ,9 ,10 ]
Arbiv, Adi [3 ]
Dalal, Ilan [11 ,12 ]
Brami, Ido [4 ]
Wormser, Ohad [5 ,6 ]
Levy, Jacov [2 ]
Roifman, Chaim M. [7 ,8 ,9 ,10 ]
机构：
[1] Soroka Univ, Med Ctr, Pediat Dept A, Beer Sheva, Israel
[2] Soroka Univ, Med Ctr, Immunol Clin, Beer Sheva, Israel
[3] Ben Gurion Univ Negev, Primary Immunodeficiency Res Lab, Fac Hlth Sci, Beer Sheva, Israel
[4] Ben Gurion Univ Negev, Dept Clin Biochem, Fac Hlth Sci, Beer Sheva, Israel
[5] Ben Gurion Univ Negev, Morris Kahn Lab Human Genet, Natl Inst Biotechnol Negev, Beer Sheva, Israel
[6] Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel
[7] Univ Toronto, Canadian Ctr Primary Immunodeficiency, Toronto, ON, Canada
[8] Univ Toronto, Jeffrey Modell Res Lab Diag Primary Immunodeficie, Toronto, ON, Canada
[9] Univ Toronto, Dept Paediat, Hosp Sick Children, Div Immunol & Allergy, Toronto, ON, Canada
[10] Univ Toronto, Toronto, ON, Canada
[11] E Wolfson Med Ctr, Dept Pediat, Holon, Israel
[12] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2020年 / 145卷 / 03期
基金：
加拿大创新基金会;
关键词：
PHOSPHORYLCHOLINE;
D O I：
10.1016/j.jaci.2019.11.015
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
[No abstract available]
引用
收藏
页码：1011 / +
页数：12
相关论文
共 50 条
  • [11] Factors influencing the effect of the soluble IL-6 receptor on IL-6 responses in HepG2 hepatocytes
    Paysant, J
    Blanqué, R
    Vasse, M
    Soria, C
    Soria, J
    Gardner, CR
    CYTOKINE, 2000, 12 (06) : 774 - 779
  • [12] Oligopeptide antagonist of IL-6: a novel approach to target IL-6 activities
    Gabay, Cem
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2007, 17 (10) : 1309 - 1314
  • [13] The function of the soluble interleukin 6 (IL-6) receptor in vivo: Sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6
    Peters, M
    Jacobs, S
    Ehlers, M
    Vollmer, P
    Mullberg, J
    Wolf, E
    Brem, G
    zumBuschenfelde, KHM
    RoseJohn, S
    JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (04): : 1399 - 1406
  • [14] Immunization of IL-5 transgenic mice with an IL-6 receptor antagonist induced antibodies to IL-6 with complete neutralization of clinical and biological effects of IL-6 overexpression.
    De Benedetti, F
    Pignatti, P
    Vivarelli, M
    Meazza, C
    Ciliberto, G
    Savino, R
    Martinl, A
    ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S273 - S273
  • [15] Association between interleukin-6 (IL-6) and IL-6 receptor (IL6-R) haplotypes and amniotic fluid IL-6 concentrations in preterm birth
    Velez, Digna R.
    Menon, Ramkumar
    Fortunato, Stephen J.
    Williams, Scott M.
    REPRODUCTIVE SCIENCES, 2008, 15 (02) : 265A - 265A
  • [16] IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6
    Rose-John, Stefan
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2012, 8 (09): : 1237 - 1247
  • [17] Higher sensitivity of IL-6 deficient mice to chemical oxidative hepatotoxicity and in vivo protection by an IL-6 receptor IL-6 chimera
    Katz, A
    Chebath, J
    Friedman, J
    Revel, M
    EUROPEAN CYTOKINE NETWORK, 1998, 9 (03) : 329 - 329
  • [18] ANALYSIS OF INTERLEUKIN 6 (IL-6)/IL-6 RECEPTOR SYSTEM USING MONOCLONAL ANTI-IL-6 ANTIBODIES
    SHIMAMURA, T
    TAKI, S
    HONDA, H
    YOKOTA, M
    ITO, S
    TAKAHARA, Y
    MOLECULAR IMMUNOLOGY, 1991, 28 (11) : 1155 - 1161
  • [19] Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What’s the Difference?
    Ali Berkant Avci
    Eugen Feist
    Gerd Rüdiger Burmester
    BioDrugs, 2018, 32 : 531 - 546
  • [20] IL-6/IL-6 receptor system and its role in physiological and pathological conditions
    Mihara, Masahiko
    Hashizume, Misato
    Yoshida, Hiroto
    Suzuki, Miho
    Shiina, Masashi
    CLINICAL SCIENCE, 2012, 122 (3-4) : 143 - 159
12345